http://link.springer.de/link/service/journals/10072/bibs/1022002/10220205.htm
Neurological Sciences
Abstract Volume 22 Issue 2 (2001)
pp 205-207
A. D. Sadovnick
Departments of Medical Genetics
and Medicine (Neurology), University of British Columbia, G920, Detwiller
Pavilion, VHHSC-UBC, 2211 Wesbrook Mall, V6T 2B5 Vancouver, BC, Canada
Abstract.
Disease-modifying therapies for MS
are believed to reduce the exacerbation frequency and thus perhaps improve
a patient's "quality of life".
Increasingly, such therapies are
being offered to young persons with relatively mild or very early disease.
Concerns about whom to treat, based
on knowledge about the role of genetics on "MS risk" and the possible teratogenic
effects of disease-modifying treatments on a developing fetus, are discussed.
© Springer-Verlag Italia 2001